Since August 26, the share price of GENFLEET-B (02595) has been on a one-sided downward trajectory, accumulating a decline of nearly 20% over 13 trading sessions. The primary driver is the broader pullback in Hong Kong-listed pharmaceutical stocks, with the Hang Seng Healthcare Index falling 6.59% over the same period. However, the factor causing the company to underperform the sector lies in the impending reduction of stakes by major shareholders. According to sources, a lock-up period for approximately 235 million shares, representing around 63.56% of the total share capital, will expire on September 19, marking 12 months since the company's Hong Kong listing. Prior to this, the World Conference on Lung Cancer (WCLC) is scheduled to take place from September 12 to 15, where the company will deliver an oral presentation on the latest study data for its core asset, GFH375, in treating KRAS G12D-mutant NSCLC. The outcomes of these two key events are likely to serve as critical indicators for the short-term price direction of the stock.

Lock-Up Expiry Jitters Weigh on Share Performance

From a market perspective, the persistent decline in the stock price of GENFLEET-B can be attributed to the expectation of the share unlock, prompting capital to refrain from assigning a high liquidity premium before clinical catalysts materialize. The direct reason for the near-20% drop in recent days is clearly the upcoming second wave of lock-up expiries on September 19. Data shows this is the second batch of shareholder lock-up expiries following the cornerstone investor unlock in March. Unlike the previous round, this involves 235 million shares held by 47 shareholders, representing approximately 61.31% of the total share capital, with a corresponding market value of HK$6.111 billion at risk. The shareholders affected include Ourea Biotech (22.42 million shares, valued at approximately HK$610 million), Changxing Growth (15.09 million shares, valued at around HK$410 million), as well as the company's largest shareholder, Jianfa Pharmaceuticals (Hong Kong), which holds 43.72 million shares. Based on the average daily trading volume of approximately 2.08 million shares over the past three months, these 235 million shares represent roughly 113 trading days of total turnover.

Adding to the short-term negative pressure is a notable deposit shift observed in the Central Clearing and Settlement System. Data from the Hong Kong Stock Exchange shows that on September 3, a deposit movement occurred for GENFLEET-B, with a total deposit value of HK$1.955 billion, representing 19.65% of the issued shares. A shareholder transferred 43.73 million shares into an account at Standard Chartered Bank (Hong Kong), increasing its stake by 12.44%. This deposit ratio of 19.65% is remarkably high, effectively moving nearly 20% of the company's float into a tradable custody account. While a deposit does not necessarily mean immediate selling, as the shares could be used for pledge financing, institutional rebalancing, or long-term custody, the context of the share price already retreating from its 52-week high of HK$52.90 to HK$25.68, a decline of 51.5%, combined with the close alignment of this deposit amount with the holdings of the largest shareholder, Jianfa Hong Kong, amplifies uncertainty and intensifies short-term volatility. This reflects a market inclination to price in potential selling pressure.

Technical indicators also corroborate this thesis. Observations show that between August 26 and September 11, the closing price of GENFLEET-B dropped from HK$32.34 to HK$25.88, a decline of 19.98%. During this period, the technical picture deteriorated from a breakdown of bullish alignment to accelerating bearish momentum with a collapsing on-balance volume (OBV). The intraday OBV plummeted from 10.916 million to 2.683 million, a 75.4% reduction in net volume, indicating a severe price-volume divergence where the decline is driven by sustained net capital outflows rather than a mere price correction. Additionally, the 5-day, 10-day, 20-day, and 60-day moving averages are in a standard bearish alignment, with the price trading along the lower Bollinger Band. The RSI has fallen to 26.4, entering oversold territory, yet OBV continues to hit new lows without showing bullish divergence, suggesting that bearish momentum has not yet exhausted and the technical phase remains in an accelerating descent and bottom-seeking process. In short, while the oversold RSI and proximity to support levels raise the probability of a short-term technical rebound, the technical signals of new OBV lows, bearish moving average alignment, and lack of divergence suggest any rebound is more likely a bear-market rally or a mid-trend bounce rather than a reversal.

WCLC Data Readout Could Be Key Catalyst for Short-Term Price Action

Nevertheless, despite the heavy short-term selling pressure, it remains uncertain whether the stock will continue its one-sided decline. The upcoming data readout for its core asset could be a pivotal variable. As the company's flagship candidate, GFH375 is the world's first oral KRAS G12D inhibitor to enter Phase III clinical trials. It has also secured two Breakthrough Therapy Designations (BTDs) in China for the monotherapy treatment of KRAS G12D-mutant pancreatic cancer and NSCLC, as well as two Fast Track Designations (FTDs) from the U.S. FDA for the treatment of KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC) and NSCLC.

Notably, in previously disclosed data from the 600mg RP2D cohort of GFH375, the objective response rate (ORR) was 68.8% and the disease control rate (DCR) was 93.8% in NSCLC patients, with a safety profile primarily characterized by Grade 1-2 treatment-related adverse events (TRAEs). The incidence of Grade 3 or higher TRAEs was 27.5%, with no treatment-related deaths. On August 26, the company further announced that GFH375 has advanced to a Phase II study in first-line KRAS G12D-mutant advanced NSCLC, testing three regimens: monotherapy, in combination with cetuximab, and in combination with pemetrexed. Therefore, the upcoming WCLC presentation is not merely an academic update but, to some extent, a core event that could determine whether the stock's oversold rebound can evolve into a valuation recovery.

From this perspective, the current valuation appears to be an event-driven, left-side speculative play. Two key questions dominate market sentiment: whether the NSCLC data for GFH375 can sustain high ORR/DCR and demonstrate more mature progression-free survival (PFS) results, and whether its safety profile is sufficient to support the advancement of combination therapies as the drug moves from later-line to earlier-line settings.

To reinforce bullish signals, Wellington Investment followed up its July 15 increase of 1.3974 million shares at an average price of HK$34.69 with a further small addition in August, directly offsetting the bearishness of the deposit shift. Concurrently, the company repurchased approximately 114,000 H-shares on September 2 and September 9, a modest buyback aimed at strengthening market confidence. With the stock in oversold territory, combined with fundamental performance and these bullish signals, there is growing divergence among southbound investors. This shift became apparent following the deposit movement. Although the deposit news leans negative, the subsequent trading sessions did not see a surge in panic selling; instead, volume shrank considerably. This indicates that the current selling pressure stems more from buyer hesitation than concentrated unloading, with the market awaiting the future handling of the deposited shares and the GFH375 clinical data. On September 9, daily volume recovered to 1.49 million shares, with a turnover rate of 0.42%, corresponding to a net increase of 314,400 shares held by southbound capital. Over the past five days, there has been a cumulative net increase of 675,000 shares, suggesting that bullish funds are beginning to accumulate at lower levels.

These dynamics further underscore that the key point of contention in the market is how the large block of deposited shares will ultimately be managed. Should the GFH375 data read out strongly at the WCLC, the stock's deposit-related pressure could be offset by fundamental catalysts. However, in the event of weaker-than-expected results, the deposited shares could transition from potential to actual selling pressure.